Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul 31;14(7):2383-2386.
doi: 10.21037/tlcr-2025-364. Epub 2025 Jul 22.

The role of perioperative chemoimmunotherapy in resectable non-small cell lung cancer: insights from the NADIM trial

Amira de Koning  1 , Ilias Houda  1   2 , Ezgi B Ulas  1   2 , Idris Bahce  1   2
Affiliations
Editorial

The role of perioperative chemoimmunotherapy in resectable non-small cell lung cancer: insights from the NADIM trial

Amira de Koning et al. Transl Lung Cancer Res. .
No abstract available

Keywords: NADIM trial; Non-small cell lung cancer (NSCLC); perioperative chemoimmunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-364/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 10.3322/caac.21660 - DOI - PubMed
    1. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016;11:39-51. 10.1016/j.jtho.2015.09.009 - DOI - PubMed
    1. Provencio M, Nadal E, Insa A, et al. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. Lancet Oncol 2024;25:1453-64. Erratum in: Lancet Oncol 2024;25:e542. 10.1016/S1470-2045(24)00498-4 - DOI - PMC - PubMed
    1. Cascone T, Awad MM, Spicer JD, et al. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med 2024;390:1756-69. 10.1056/NEJMoa2311926 - DOI - PubMed
    1. Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med 2023;389:1672-84. 10.1056/NEJMoa2304875 - DOI - PubMed